Gene · 7317
Papers2,562
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,562
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Macrocytosis combined with monoclonal gammopathy identifies patients carrying VEXAS-linked UBA1 mutations. | Hemasphere | 2026 | 42524406 | PubTator, text mining | PubMed |
| Somatic UBA1 mutations in pediatric MDS/AML: first cases suggest distinct pathogenesis from adult VEXAS syndrome. | Blood Neoplasia | 2026 | 42519172 | PubTator, text mining | PubMed |
| VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome in a Patient Presenting With Auricular Chondritis. | Cureus | 2026 | 42516444 | PubTator, text mining | PubMed |
| VEXAS Mimicking Antiphospholipid Syndrome: Diagnostic Challenges of False-Positive Antiphospholipid Antibodies. | Int J Mol Sci | 2026 | 42511538 | PubTator, text mining | PubMed |
| Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome: An emerging autoinflammatory paraneoplastic disorder. | Clin Dermatol | 2026 | 42503337 | PubTator, text mining | PubMed |
| Quercetin, a flavonoid, suppresses viral proliferation by interfering with the ubiquitin transfer from E1 to E2 enzymes. | PLoS Pathog | 2026 | 42475393 | PubTator, text mining | PubMed |
| VEXAS syndrome presenting with severe cutaneous manifestations, inflammatory arthritis, and myelodysplastic syndrome treated with Ruxolitinib. | Oxf Med Case Reports | 2026 | 42438666 | PubTator, text mining | PubMed |
| Progressive macrocytic anaemia over 14 years leading to the diagnosis of VEXAS syndrome in a patient initially diagnosed with adult-onset Still's disease. | Mod Rheumatol Case Rep | 2026 | 42436642 | PubTator, text mining | PubMed |
| Dual somatic UBA1 Met41 variants with distinct allele frequencies in VEXAS syndrome. | EULAR Rheumatol Open | 2026 | 42434418 | PubTator, text mining | PubMed |
| Dysfunctional UBA1-mutated myeloid cells promote inflammation in VEXAS syndrome. | Nat Rev Rheumatol | 2026 | 42410236 | PubTator, text mining | PubMed |
| VEXAS syndrome unmasked from relapsing polychondritis and infection mimicry: a case-based review. | Rheumatol Int | 2026 | 42405976 | PubTator, text mining | PubMed |
Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Mimicking Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Delayed Diagnosis in a Patient With Multisystem Inflammation and Neutrophilic Dermatosis. | Cureus | 2026 | 42403819 | PubTator, text mining | PubMed |
| A Sex-Specific Chimeric RNA in Female Immune Regulation: Case Study. | Methods Mol Biol | 2026 | 42400799 | PubTator, text mining | PubMed |
| Protocol for integrated ubiquitination analysis of in vitro E3 ligase-DUB regulation and in vivo ubiquitin chain linkage characterization. | STAR Protoc | 2026 | 42397747 | PubTator, text mining | PubMed |
| Variable vessel vasculitis of arteries and veins in VEXAS syndrome. | BMJ Case Rep | 2026 | 42362343 | PubTator, text mining | PubMed |
| Trisomy 8 clonal expansion during disease progression and azacitidine resistance in VEXAS syndrome: a case report. | Front Immunol | 2026 | 42358941 | PubTator, text mining | PubMed |
| VEXAS Syndrome Beyond UBA1: Genetic Architecture and the Role of Co-Occurring Somatic Mutations-A Focused Review. | Genes (Basel) | 2026 | 42353870 | PubTator, text mining | PubMed |
| Mechanism of auranofin toxicity: Inhibition of tetrahydrobiopterin metabolism. | Toxicol Appl Pharmacol | 2026 | 42334839 | PubTator, text mining | PubMed |
| A case of glucocorticoid-resistant VEXAS syndrome successfully treated with baricitinib. | Mod Rheumatol Case Rep | 2026 | 42329752 | PubTator, text mining | PubMed |
| Drug-Free Remission of VEXAS Syndrome Without Stem Cell Transplantation. | Cureus | 2026 | 42326195 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7317/papers?page=2